239 related articles for article (PubMed ID: 21737266)
21. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
[TBL] [Abstract][Full Text] [Related]
22. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Washburn WN
J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
[No Abstract] [Full Text] [Related]
23. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors.
Yan Q; Ding N; Li Y
Carbohydr Res; 2016 Feb; 421():1-8. PubMed ID: 26735747
[TBL] [Abstract][Full Text] [Related]
25. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
[TBL] [Abstract][Full Text] [Related]
26. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
[TBL] [Abstract][Full Text] [Related]
27. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
[TBL] [Abstract][Full Text] [Related]
28. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
29. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.
Park EJ; Kong Y; Lee JS; Lee SH; Lee J
Bioorg Med Chem Lett; 2011 Jan; 21(2):742-6. PubMed ID: 21193308
[TBL] [Abstract][Full Text] [Related]
30. 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.
Xu G; Du F; Kuo GH; Xu JZ; Liang Y; Demarest K; Gaul MD
Bioorg Med Chem Lett; 2020 Sep; 30(17):127387. PubMed ID: 32738984
[TBL] [Abstract][Full Text] [Related]
31. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
32. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
[TBL] [Abstract][Full Text] [Related]
33. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374
[TBL] [Abstract][Full Text] [Related]
34. C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.
Robinson RP; Mascitti V; Boustany-Kari CM; Carr CL; Foley PM; Kimoto E; Leininger MT; Lowe A; Klenotic MK; Macdonald JI; Maguire RJ; Masterson VM; Maurer TS; Miao Z; Patel JD; Préville C; Reese MR; She L; Steppan CM; Thuma BA; Zhu T
Bioorg Med Chem Lett; 2010 Mar; 20(5):1569-72. PubMed ID: 20149653
[TBL] [Abstract][Full Text] [Related]
35. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
[TBL] [Abstract][Full Text] [Related]
36. C-Aryl Glucosides with Substituents at the Distal Aryl Ring as Sodium-Dependent Glucose Cotransporter Inhibitors for the Treatment of Diabetes Mellitus.
Wang X; Li Y; Yang B; Li Z; Huang W; Qian H
Chem Biol Drug Des; 2015 Aug; 86(2):246-53. PubMed ID: 25443983
[TBL] [Abstract][Full Text] [Related]
37. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis and in vivo Evaluation of Novel C-Aryl Glucosides as Potent Sodium-Dependent Glucose Cotransporters Inhibitors for the Treatment of Diabetes.
Li Z; Wang X; Xu X; Qiu Q; Jiao L; Huang W; Qian H
Chem Biol Drug Des; 2015 Oct; 86(4):764-75. PubMed ID: 25732240
[TBL] [Abstract][Full Text] [Related]
39. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Ohtake Y; Sato T; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Yamaguchi M; Takami K; Yeu SY; Ahn KH; Matsuoka H; Morikawa K; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
J Med Chem; 2012 Sep; 55(17):7828-40. PubMed ID: 22889351
[TBL] [Abstract][Full Text] [Related]
40. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
Lee SH; Kim MJ; Lee SH; Kim J; Park HJ; Lee J
Eur J Med Chem; 2011 Jul; 46(7):2662-75. PubMed ID: 21514014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
